AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 32 min read$TNGX

Crystal Adam sold $481K of TNGX

Crystal Adam (President, R&D) sold 20,860 shares of Tango Therapeutics, Inc. (TNGX) at $23.06 ($0.48M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Crystal Adam
Published Jun 3, 2026, 10:37 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 10:41 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TNGX
Neutral
medium confidence
Mentioned
$TNGX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TNGXNeutralLow
01

Why it matters

The main trading relevance is sentiment/positioning around insider activity; absent accompanying corporate news, it is unlikely to drive a sustained repricing.

02

Market read

A disclosed, planned insider sale may slightly pressure sentiment, but the 10b5-1 structure limits fundamental interpretation.

03

What to watch

The filing does not reveal whether the officer sold for diversification, liquidity needs, or routine plan execution; holdings remain substantial (115,743 shares after).

Relevance 6/10Novelty 6/10Timing: Filed after-hours (2026-06-03) for a sale executed 2026-06-01

Background

This is an SEC Form 4 insider transaction disclosure (officer/direct holding) for Tango Therapeutics, executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$TNGXNeutralMedium confidence
Context

Tango Therapeutics disclosed an officer (President, R&D) open-market sale of 20,860 shares via SEC Form 4 on a 10b5-1 plan.

Expected impact

Likely limited/short-lived impact unless accompanied by unusual volume or additional disclosures.

Evidence & confidence

Form 4 shows a pre-arranged 10b5-1 sale, which typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

Small read-through for biotech insider-sentiment, but no sector-wide catalyst is indicated.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is on a 10b5-1 plan, the market may overreact; price reaction (if any) could fade quickly.

Key entities

  • issuer
    Tango Therapeutics, Inc.

    Subject of the Form 4 insider sale by its President, R&D.

  • insider
    Crystal Adam

    President, R&D who sold 20,860 shares at ~$23.0558/share under a 10b5-1 plan.

Read at source← All news

Related articles

JUL 15
$TNGXMed

Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues

Canaccord Genuity raised its price target for Tango Therapeutics (NASDAQ:TNGX) to $46 from $42 and kept a Buy rating, citing a revised model that includes combined revenues from vopimetostat plus KRAS inhibitors in NSCLC. Jefferies upgraded TNGX to Buy and lifted its target to $60. Tango also signed an underwriting for about 18.2M shares plus pre-funded warrants, expecting ~$566.5M net proceeds for trials and R&D.

yahoo.com5 min
JUN 8
$TNGXMedAI 9/10

Tango Therapeutics Announces Proposed $500 Million Public Offering

Tango Therapeutics (Nasdaq: TNGX) announced a proposed underwritten public offering of $500 million of its common stock, with all shares to be sold by the company. The underwriters may be granted a 30-day option to buy up to an additional $75 million of shares. J.P. Morgan, Leerink Partners, Cantor and Stifel are joint bookrunners.

manilatimes.net4 min
JUN 8
$TNGXHighAI 8/10

Tango's Combo Therapy Shows 92% Response In Pancreatic Cancer; Stock Up

Tango Therapeutics (TNGX) shares rose after early Phase 1/2 results for Vopimetostat plus Revolution Medicines’ RAS(ON) inhibitor Daraxonrasib in MTAP-deleted, RAS-mutant metastatic pancreatic ductal adenocarcinoma. The company reported a 92% objective response rate; at six months, 90% were progression-free and median PFS was not reached. Both regimens were generally well tolerated, and Tango plans Phase 3 first-line development later in 2026.

rttnews.com4 min